Patient Profiles
The profiles below represent examples of Optune Lua patient types
Explore patient profiles
Example patient case;
actor portrayal.
- Patient had durable response to IO + platinum-doublet, now with slow progression during maintenance IO
Example patient case;
actor portrayal.
- Motivated patient with multiple rapidly progressing lesions who wants to explore treatment options
Example patient case;
actor portrayal.
- Patient with high PD-L1 status who initially avoided IO due to an autoimmune comorbidity, now with progression
Key Clinical Characteristics from LUNAR1
- Stage: IV
- Line: 2L+
- ECOG: 0-2
- Adult patients
- Not pregnant, trying to get pregnant, might be pregnant, or breastfeeding
- Does not have a known sensitivity to gel used with Optune Lua
- Progression on or after platinum-based chemotherapy
- No implantable electronic medical devices in the upper torso (eg, pacemaker) or active CNS metastases
Based on the broad study population, Optune Lua may be appropriate regardless of:
- Histology
- PD-L1 status2
- Driver mutations
- Smoking status
- Site of metastases
Patient Motivation and Goals
- Patients who want more control over their therapy (ie, want to be active participants)
- Chemo-averse patients who reject/resist chemo overall or don’t want it again after 1L
- Patients who are motivated to extend survival
David
55 years old
25% PD-L1, stage IVa squamous cell NSCLC Durable response to IO + platinum-based chemo, now with slow progression during maintenance IO
“My doctor thinks IO is still working for me, although my cancer has shown signs of progression.*”
Patient History
• Coronary artery disease, hypertension; 30 pack-years
• ECOG PS 0
History of Present Illness
- 5-cm mass and a 1.5-cm nodule in the right lung, with mediastinal and supraclavicular lymphadenopathy
- Squamous cell carcinoma with no targetable driver mutations
- 25% PD-L1 expression
Treatment History
- Pembrolizumab + carboplatin-paclitaxel Q3W for 4 cycles, with continuation of pembrolizumab Q3W for 25 cycles
Current Disease Status
- Demonstrated slow progression to the left lung after 75 weeks on pembrolizumab
- Now with a nodule close to 1 cm in size and mild pleural-based progression, but remaining mostly asymptomatic
Laura
73 years old
PD-L1 negative, stage IVb squamous cell NSCLC
Motivated patient with rapidly progressing multiple new lesions
“I’m willing to try whatever treatment option my doctor recommends.*”
Patient History
- Married, adult children, retired
- Person with smoking history
- Coronary artery disease, hypertension, type 2 diabetes
- ECOG PS 1
History of Present Illness
- Stage IVb NSCLC: multiple small, bilateral lung nodules and a liver lesion
- Squamous cell carcinoma with no targetable driver mutations
- PD-L1 negative
Treatment History
- Nivolumab + ipilimumab + carboplatin-paclitaxel for 2 cycles, followed by nivolumab + ipilimumab for 6 cycles
Current Disease Status
- Five months after initiating treatment, the patient experienced progressive disease with new bone lesions in the lower spine and a few small liver lesions
Susan
60 years old
75% PD-L1, stage IVa nonsquamous NSCLC
Avoided 1L IO due to autoimmune comorbidity
“I am exploring treatment options that will extend my survival.*”
Patient History
- Widowed with a caregiver, adult children. First grandchild due in 6 months
- Never smoker
- On active treatment for her autoimmune comorbidity
- ECOG PS 1
History of Present Illness
- Stage IVa NSCLC: referred from rheumatologist. Single lung mass of 6 cm in diameter, with a 1.3-cm liver lesion
- Nonsquamous cell carcinoma with no targetable driver mutations
- 75% PD-L1 expression
Treatment History
- Carboplatin/pemetrexed for 4 cycles with continued pemetrexed. IO was avoided given the history of her autoimmune comorbidity
Current Disease Status
- Radiologic assessment showed stable disease for 3 months, but she now has progressive disease in the lung and liver
Actor portrayals.
Review guidelines for managing skin-related adverse reactions
1L, first line; 2L+, second line or after; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; IO, immuno-oncology agent; mNSCLC, metastatic non–small cell lung cancer; NSCLC, non–small cell lung cancer; OS, overall survival; PD-1/PD-L1, programmed cell death 1 protein/programmed cell death 1 ligand 1; Q3W, every 3 weeks.
References: 1. Optune Lua for Non-Small Cell Lung Cancer (NSCLC). Physician Instructions for Use. Novocure; 2024. 2. Novocure Data on File GLB-DOF-0020.